Search 

2M Biotech is a family office investment vehicle founded in 29 and based in Dallas Texas. The firm manages an evergreen structure and is looking to make equity investments into companies ranging from $.5 ? $5 million with a preference for the middle of that range. The firm is also willing to co-invest with investors they either know well or are able to get a strong reference for. The firm looks to invest in Seed and Series A rounds and looks to take a significant stake in the company?s equity. The firm prefers to invest in companies that are not located in an areas highly saturated with venture capital. The firm plans to make 3-4 new investments over the next 12 months.

AbbVie was founded by Abbott Laboratories in 213 and is based in Chicago IL. The firm partners with developmental-stage biotech companies and is actively seeking to in-license therapeutic assets. AbbVie generally seeks global rights to assets and will consider partnerships worldwide, the firm licenses assets opportunistically with no set rate of allocations. AbbVie also has a venture arm that makes equity investments AbbVie Venture & Early-Stage Collaborations.

Action Potential Venture Capital is an evergreen strategic venture capital fund of GlaxoSmithKline which closed at $1 million in 213 and is managed by a small dedicated team based in Cambridge Massachusetts and Palo Alto California. The fund focuses on investments in companies developing pioneering bioelectronic medicines (essentially neuromodulation devices) and related enabling technologies. The initial investments are typically ranging from $5-$7 million in Series A and the fund will also consider follow-on investments. Action Potential Venture Capital looks for investment opportunities globally.

The Addario Lung Cancer Medical Institute (ALCMI), founded in 2008 as a 501c(3) non-profit organization, is a patient-centric, international research consortium driving research otherwise not possible, evidenced by ALCMI's current clinical studies CASTLE, INHERIT EGFR T790M, Genomics of Young Lung Cancer and others. ALCMI overcomes barriers to collaboration via a world-class team of investigators from 21+ institutions in the U.S., France, Italy, Spain and U.K., supported by dedicated research infrastructures such as centralized project management, tissue banks and data systems. ALCMI directly facilitates research by combining scientific expertise found at leading academic institutions with patient access through our network of community cancer centers – accelerating novel research advancements to lung cancer patients. 

Adjuvant Therapeutics Inc. is a clinical stage medical device company that is developing a system to improve the effectiveness of radiotherapy for cancer treatment. The system, called OncO2™, uses innovative technology to increase oxygen concentrations in tumours, making them more sensitive to radiation.

Poor tumour oxygen has long been known to make radiation less effective, particularly in cancers of the head and neck, where 5 year survival rates range from 17% to about 63%. The OncO2™ system allows for individual optimization of therapy to maximize the effectiveness of the radiation.

Adjuvant Therapeutics will initially focus on head and neck cancers, however the OncO2™ system can also address other types of resistant cancers such as those of the cervix and bladder.

Advent Life Sciences

We invest predominantly in early and mid-stage life sciences companies.  We seek to back truly innovative companies that have a first-in-class or best-in-class approach and who are looking for a well-connected partner on the road to success.

Our investments cover a range of sectors within life sciences, including new drug discovery, enabling technologies, med tech and diagnostics.Advent Life Sciences is one of Europe’s leading venture teams investing in life sciences businesses. We are a deliberately small, and highly focused team of senior individuals, with long-standing track records of entrepreneurial and investment success across the UK, Europe and the USA.

Real people. Real insight. Real value.

Innovation. Clarity. Execution.

 

 

AFH Holding & Advisory LLC is a boutique investment banking firm that offers financial advisory services. The firm focuses on alternative public offerings marketing strategy planning capital structuring and mergers and acquisitions advisory. Its clientele include Carlisi Natural Gas Inc. Fossil Energy Group LLC Kaikai Technology Co. Ltd. and Yi Xin Copper Co. Ltd. AFH Holding & Advisory LLC is based in Beverly Hills California with an additional office in Pudong China.

Alexion was founded in 1992 and is based in Cheshire CT. Alexion specializes in the development of treatments for ultra-orphan diseases (diseases with under 2 patients in the USA or EU) and is seeking to in-license assets in this field. Alexion prefers to acquire global rights to assets.

The American Heart Association is a non-profit foundation that was founded 1924. The firm looks to make equity investments into companies of up to $25 generally in the seed or series A stage. The firm is looking to invest in companies located throughout the United States and is currently seeking new investment opportunities.

Amorphex Therapeutics is an early clinical stage company that was founded to develop products for sustained ophthalmic drug delivery using patented TODDD™ technology. Topical ophthalmic pharmaceuticals are a $5+Billion market, but inaccurate and inefficient delivery systems, poor compliance and excessive side effects undermine their clinical benefits and true sales potential. TODDD™ is a soft, non-invasive device that is completely concealed under the eyelid and continuously delivers therapeutic levels of drug 24/7 over several months. While TODDD™ is soft and flexible, unlike soft contact lenses, it doesn’t contain appreciable water and avoids the surface drying and resulting deposits that irritate and deter many contact lens wearers. In recognition of the potential benefits and their developmental progress, the company’s founders have been awarded three National Institutes of Health (NIH-SBIR) grants for the TODDD™ technology totaling $2.5 million.

TODDD™ has issued patents in major markets and has been successfully tested in safety studies, animal trials with drugs and without drug in humans.

Amorphex is seeking to fund small, 30 - 40 subject, human clinical trials of TODDD™ delivering timolol, prostaglandin and both drugs simultaneously. This funding will also support pre-clinical development of TODDD™ for ocular allergy and inflammation applications.  These milestones will drive dramatic increases in valuation and corporate partner interest.